ReviewThe oncologist2014
Adjuvant therapy for renal cell carcinoma: past, present, and future.
Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.JAMA oncology · 2017Trial
- Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.JAMA oncology · 2017Trial
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.Lancet (London, England) · 2016Trial
- MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker.Cell death & disease · 2025Article
- Heterogeneity in NK Cell Subpopulations May Be Involved in Kidney Cancer Metastasis.Journal of immunology research · 2022Article
- Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis.Frontiers in oncology · 2021Article
- Surgical intervention in renal cell carcinoma patients with lung and bronchus metastasis is associated with longer survival time: a population-based analysis.Annals of translational medicine · 2019Article
- The adjuvant treatment of kidney cancer: a multidisciplinary outlook.Nature reviews. Nephrology · 2019Review
- Adjuvant therapy in renal cell carcinoma: the perspective of urologists.International journal of clinical oncology · 2019Article
- Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?Current treatment options in oncology · 2019Review
- Overexpression of SNHG12 regulates the viability and invasion of renal cell carcinoma cells through modulation of HIF1α.Cancer cell international · 2019Article
- Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.Current oncology (Toronto, Ont.) · 2018Review
- Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Cystic Duct Metastasis from Renal Cell Carcinoma.Internal medicine (Tokyo, Japan) · 2018Article
- Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study.Translational oncology · 2017Article
- Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.JCI insight · 2017Article
- Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.Kidney cancer (Clifton, Va.) · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance. With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.